Christoph H Westphal
CIK 1291961 · President and CEO · last filed 2021-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FLKS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 THIRD STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TCRX | 10%+ Owner | 1,036,585 | $0.19 | $201.7K | $2.00M | 1 | 2021-07-22 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | President and CEO | 157,645 | — | — | $3.19M | 65 | 2018-10-18 |
| VSTM | Executive Chairman | 65,911 | $10.05 | $662.4K | $8.08M | 28 | 2015-07-01 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 47,118 | — | — | $1.05M | 3 | 2014-03-11 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | President and CEO | 744,053 | — | — | -$733.3K | 8 | 2008-05-30 |
Recent Filings · Page 9 of 11
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-09-12 | Tempest Therapeutics, Inc. (OVAS) Delisted | Buy (P) | +4,850 | $51.1K | EDGAR |
| 2013-07-02 | VSTM | Tax (F) | −5,923 | -$82.2K | EDGAR |
| 2013-06-11 | VSTM | Mixed | +1,800 | $16.6K | EDGAR |
| 2013-06-11 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-23 | VSTM | Mixed | +1,600 | $15.2K | EDGAR |
| 2013-05-07 | VSTM | Mixed | +1,600 | $15.8K | EDGAR |
| 2013-04-19 | VSTM | Mixed | +1,800 | $16.7K | EDGAR |
| 2013-04-03 | VSTM | Mixed | −5,042 | -$47.5K | EDGAR |
| 2013-03-25 | VSTM | Mixed | +1,600 | $14.7K | EDGAR |
| 2013-03-14 | VSTM | Tax (F) | −36,864 | -$345.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.